Bupropion: a review of its mechanism of antidepressant activity

• Published in: The journal of clinical psychiatry Vol. 56; no. 9; p. 395
• Main Authors: Ascher, J A, Cole, J O, Colin, J N, Feighner, J P, Ferris, R M, Fibiger, H C, Golden, R N, Martin, P, Potter, W Z, Richelson, E
• Format: Journal Article
• Language: English
• Published: United States 01.09.1995
• Subjects: Animals; Antidepressive Agents - pharmacology; Antidepressive Agents - therapeutic use; Brain - drug effects; Brain - metabolism; Bupropion - pharmacology; Bupropion - therapeutic use; Depressive Disorder - drug therapy; Depressive Disorder - psychology; Dopamine - metabolism; Down-Regulation - drug effects; Humans; Locus Coeruleus - drug effects; Mice; Microdialysis; Neurons - drug effects; Norepinephrine - metabolism; Raphe Nuclei - drug effects; Rats; Receptors, Adrenergic, beta - drug effects; Serotonin - metabolism; Synaptic Transmission - drug effects; Treatment Outcome
• ISSN: 0160-6689

The mechanism of action of the novel antidepressant bupropion remains unclear after many years of study. A review of the relevant biochemical, in vivo brain microdialysis, electrophysiologic, behavioral, and clinical data clarifies what is known about this unique compound and suggests possible modes of action. A panel of 11 experts was convened for a conference to discuss bupropion's mechanism of antidepressant activity. Four of the panelists presented current research findings, followed by a discussion. (1) Biochemical studies suggest down-regulation of postsynaptic beta-adrenoceptors and desensitization of the norepinephrine-stimulated adenylate cyclase in the rat cortex occur only after chronic administration of very high doses of bupropion. (2) In vivo brain microdialysis studies demonstrate that, after chronic administration, there is an enhancement of bupropion-induced increases in extracellular dopamine in the nucleus accumbens. (3) Electrophysiologic data show that with acute dosing, bupropion reduces the firing rates of noradrenergic neurons in the locus ceruleus. The firing rates of dopaminergic neurons are reduced by bupropion in the A9 and A10 areas of the brain, but only at very high doses, and bupropion does not alter the firing rates of serotonergic neurons in the dorsal raphe. (4) Behavioral studies show that the most active metabolite of bupropion, hydroxybupropion (306U73), appears to be responsible for a large part of the compound's effects in animal models of antidepressant activity. (5) Clinical studies indicate that bupropion enhances noradrenergic functional activity as reflected by an increased excretion of the hydroxy metabolite of melatonin, while at the same time producing a presumably compensatory decrease in norepinephrine turnover. In one study, bupropion elevated plasma levels of the dopamine metabolite homovanillic acid in nonresponders, but not in responders. The mechanism of action of bupropion appears to have an unusual, not fully understood, noradrenergic link. The bupropion metabolite hydroxybupropion probably plays a critical role in bupropion's antidepressant activity, which appears to be predominantly associated with long-term noradrenergic effects. The mild central nervous system activating effects of bupropion appear to be due to weak dopaminergic mechanisms. There is some evidence that dopamine may contribute to bupropion's antidepressant properties. Antidepressant effects of bupropion are not serotonergically mediated.